Breaking News, Financial News

AstraZeneca Revenues up 56% in the Quarter.

Oncology revenue increases 21%, Farxiga sales reach $1.0 billion, and Alexion medicines contribute $1.7 billion, helping to offset Pulmicort decline of 34%.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AstraZeneca 1Q Revenues: $11.4 billion (+56%) 1Q Earnings: $388 million (-75%) Comments: Revenue in the quarter reflects growth across the company, the contribution of the Alexion medicines and several Vaxzevria contracts that are expected to complete delivery by 1H22. Products sales include $1.7 billion from medicines acquired with Alexion.    Total revenue from Oncology increased 21% to $3.6 billion, including a milestone payment. Product sales from Oncology increased 18%, with Tagrisso s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters